Investor Centre

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

• Boehringer Ingelheim commences Phase II program of investigational drug candidate BI 1467335 acquired from Pharmaxis with a 12 week Phase IIa proof of clinical principle study in non-alcoholic steatohepatitis (NASH)
• New study underscores Boehringer Ingelheim’s aspiration to deliver more first in class medicines with breakthrough potential for patients with cardio metabolic diseases
• Pharmaxis to receive €18 million milestone payment in a significant further endorsement of the company’s ability to generate value from its early stage pipeline.

INGELHEIM, Germany and SYDNEY, Australia – August 24, 2017 – Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)[1], and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.